Bevan N - Search Results

1

Functional analysis of a human A(1) adenosine receptor/green fluorescent protein/G(i1)alpha fusion protein following stable expression in CHO cells.

Bevan N, Palmer T, Drmota T, Wise A, Coote J, Milligan G, Rees S. Bevan N, et al. FEBS Lett. 1999 Nov 26;462(1-2):61-5. doi: 10.1016/s0014-5793(99)01467-2. FEBS Lett. 1999. PMID: 10580092 Free article.

2

Nociception activates Elk-1 and Sap1a following expression of the ORL1 receptor in Chinese hamster ovary cells.

Bevan N, Scott S, Shaw PE, Lee MG, Marshall FH, Rees S. Bevan N, et al. Neuroreport. 1998 Aug 24;9(12):2703-8. doi: 10.1097/00001756-199808240-00003. Neuroreport. 1998. PMID: 9760105

3

Visualizing differences in ligand regulation of wild-type and constitutively active mutant beta(2)-adrenoceptor-green fluorescent protein fusion proteins.

McLean AJ, Bevan N, Rees S, Milligan G. McLean AJ, et al. Among authors: bevan n. Mol Pharmacol. 1999 Dec;56(6):1182-91. doi: 10.1124/mol.56.6.1182. Mol Pharmacol. 1999. PMID: 10570045

4

Detection of receptor ligands by monitoring selective stabilization of a Renilla luciferase-tagged, constitutively active mutant, G-protein-coupled receptor.

Ramsay D, Bevan N, Rees S, Milligan G. Ramsay D, et al. Among authors: bevan n. Br J Pharmacol. 2001 May;133(2):315-23. doi: 10.1038/sj.bjp.0704077. Br J Pharmacol. 2001. PMID: 11350868 Free PMC article.

5

Pharmaceutical applications of GFP and RCFP.

Bevan N, Rees S. Bevan N, et al. Methods Biochem Anal. 2006;47:361-89. doi: 10.1002/0471739499.ch16. Methods Biochem Anal. 2006. PMID: 16335721 Review. No abstract available.

6

Mammalian expression of transmembrane receptors for pharmaceutical applications.

Rhodes AD, Bevan N, Patel K, Lee M, Rees S. Rhodes AD, et al. Among authors: bevan n. Biochem Soc Trans. 1998 Nov;26(4):699-704. doi: 10.1042/bst0260699. Biochem Soc Trans. 1998. PMID: 10047810 Review.

7

Resolution of inverse agonist-induced up-regulation from constitutive activity of mutants of the alpha(1b)-adrenoceptor.

Stevens PA, Bevan N, Rees S, Milligan G. Stevens PA, et al. Among authors: bevan n. Mol Pharmacol. 2000 Aug;58(2):438-48. doi: 10.1124/mol.58.2.438. Mol Pharmacol. 2000. PMID: 10908313

8

Application of beta-galactosidase enzyme complementation technology as a high throughput screening format for antagonists of the epidermal growth factor receptor.

Graham DL, Bevan N, Lowe PN, Palmer M, Rees S. Graham DL, et al. Among authors: bevan n. J Biomol Screen. 2001 Dec;6(6):401-11. doi: 10.1177/108705710100600606. J Biomol Screen. 2001. PMID: 11788058

9

The BlueScreen-384 assay as an indicator of genotoxic hazard potential in early-stage drug discovery.

Simpson K, Bevan N, Hastwell P, Eidam P, Shah P, Gogo E, Rees S, Brown A. Simpson K, et al. Among authors: bevan n. J Biomol Screen. 2013 Apr;18(4):441-52. doi: 10.1177/1087057112470858. Epub 2012 Dec 20. J Biomol Screen. 2013. PMID: 23264450

10

Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach.

Procopiou PA, Barrett VJ, Bevan NJ, Biggadike K, Box PC, Butchers PR, Coe DM, Conroy R, Emmons A, Ford AJ, Holmes DS, Horsley H, Kerr F, Li-Kwai-Cheung AM, Looker BE, Mann IS, McLay IM, Morrison VS, Mutch PJ, Smith CE, Tomlin P. Procopiou PA, et al. J Med Chem. 2010 Jun 10;53(11):4522-30. doi: 10.1021/jm100326d. J Med Chem. 2010. PMID: 20462258

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page